Date: 2012-09-13
Type of information: Commercialisation agreement
Compound: Gelclair®
Company: Helsinn (Switzerland) DARA BioSciences (USA)
Therapeutic area: Cancer - Oncology
Type agreement: commercialisation
Action mechanism: Gelclair® is a topical gel used to coat and protect the oral cavity to reduce pain.
Disease: oral mucositis
Details: The Helsinn Group has entered into an exclusive agreement with DARA BioSciences, for U.S. commercial rights to Gelclair®. DARA plans to launch Gelclair® in the first quarter of 2013. DARA has increased its focus in oncology treatment and supportive care products through its January 2012 acquisition of Oncogenerix. The company has already licensed four agents: Bionect® a topical treatment for skin irritation and burns associated with radiation therapy, Soltamox® an oral liquid formulation of tamoxifen citrate, and Gelclair®, and a fourth, gemcitabine, due for ANDA submission by end of 2012. These operations are of DARA\'s strategy to build a portfolio of niche opportunity products for the oncology and oncology supportive care markets. Its product portfolio also includes KRN5500, a novel therapy under development for the treatment of neuropathic pain in patients with cancer, a condition with no current adequate therapy.
Financial terms: Financial details were not disclosed.
Latest news:
